Company news
Axim Biotechnologies, Inc. (OTC:AXIM) news
Axim Biotechnologies, Inc. news releases on 6ix. Latest, Aug 30, 2021: AXIM® Biotechnologies’ Manufacturing Partner Empowered Diagnostics Files Amended…
Press releases — page 2
AXIM® Biotechnologies’ Manufacturing Partner Empowered Diagnostics Files Amended Emergency Use Authorization with FDA for its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations
August 30, 2021
AXIM® Biotechnologies to Acquire Technology Including Two FDA-Cleared 510(k)’s for Diagnostic Testing of Dry Eye Disease
August 3, 2021
AXIM® Biotechnologies Completes Pre-Clinical Drug Studies on SPX-1009 Compound Proving Suppression of Melanoma Cells
May 26, 2021
AXIM® Biotechnologies’ Manufacturing Partner Empowered Diagnostics Files for Approval for Use of Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations in Canada and the EU
May 5, 2021
AXIM Biotechnologies Introduces Diagnostics to Measure Immunity Against Emerging SARS-CoV-2 Variants
May 3, 2021
AXIM® Biotechnologies’ Manufacturing Partner Empowered Diagnostics Files Emergency Use Authorization With FDA for Use of Its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations
March 24, 2021
AXIM® Biotechnologies Successfully Completes Point-of-Care Clinical Trials on its Rapid COVID-19 Neutralizing Antibody Test
March 8, 2021
AXIM® Biotechnologies Begins Clinical Trials on Its ImmunoPass Rapid Diagnostic Test With Vaccine Recipients
February 3, 2021
AXIM® Biotechnologies Releases Preprint Manuscript Describing the Development of Company’s Rapid Point-of-Care Test That Measures COVID-19 Neutralizing Antibodies
January 11, 2021
AXIM® Biotechnologies Completes Successful Covid-19 Live Virus Test and Files Amended EUA for Portable 10 Minute Rapid Diagnostic Test for Neutralizing Antibodies
December 15, 2020
AXIM® Biotechnologies to Present at the 13th Annual LD Micro Main Event Investor Conference on Monday, December 14
December 14, 2020
AXIM® Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company’s Fourth COVID-19 Test-Focused Patent Application
December 3, 2020
AXIM® Biotechnologies Applauds Vaccine Producers, Highlights Need for Rapid Antibody Testing to Ensure Immunity
November 10, 2020
AXIM® Biotechnologies Issues Update Letter to Shareholders
October 28, 2020
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Files Patent for World’s First Face Mask Designed to Capture SARS-CoV-2 (COVID-19)
October 6, 2020
AXIM® Biotechnologies Files Patent for Virus Binding Recombinant Protein for SARS-CoV-2 (COVID-19) and Begins Manufacturing
September 30, 2020
AXIM® Biotechnologies Files Patent for World’s First Face Mask Designed to Capture SARS-CoV-2 COVID-19
September 29, 2020
AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Proprietary Compounds and Methods Targeting Tumor Metastasis Through QSOX1
September 22, 2020
AXIM® Biotechnologies Files Emergency Use Authorization With the FDA for First–in-Class COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies
September 16, 2020
AXIM® Biotechnologies Signs Exclusive Licensing, Manufacturing and Distribution Agreement for High Volume Production of the COVID-19 Rapid Neutralizing Antibody Test
August 24, 2020
Sapphire Biotech, Subsidiary of AXIM® Biotechnologies, Awarded Prestigious Phase I Small Business Innovation Research Grant by National Cancer Institute
August 11, 2020
AXIM® Biotechnologies Applies for FDA Emergency Use Approval (EUA) for High Throughput, Patent-Pending Neutralizing Antibody Diagnostic Test for COVID-19
August 5, 2020
AXIM® Biotechnologies Releases Rapid NeuCovix™ Test Results Showing Strong Agreement with COVID-19-Based Neutralization Tests
July 23, 2020
AXIM® Biotechnologies Welcomes Former Secretary of Veterans Affairs Peter O'Rourke to Company’s Board of Directors
July 21, 2020
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Unveils World’s First COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies and Files Pre-Emergency Use Authorization
July 21, 2020
AXIM® Biotechnologies Unveils First–in-Class COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies and Files Pre-Emergency Use Authorization with the FDA
July 15, 2020
AXIM® Biotechnologies Appoints Dr. Alim Seit-Nebi as Chief Technology Officer of Subsidiary Sapphire Biotech
June 9, 2020
AXIM® Biotechnologies Begins Pre-Clinical Pharmacokinetic Animal Drug Studies on its Cancer Drug Compound SPX-1009
June 1, 2020
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Expands Research Division and Announces Dr. Sergei Svarovsky as Chief Scientific Officer of Subsidiary Sapphire Biotech
May 28, 2020
AXIM® Biotechnologies Expands Research Division and Announces Dr. Sergei Svarovsky as Chief Scientific Officer of Subsidiary Sapphire Biotech
May 27, 2020
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Files Patent for Unique Early Detection Cancer Biomarker
May 21, 2020
AXIM® Biotechnologies Files for Patent for Unique Biomarker for Early Detection of Cancer in Blood
May 18, 2020
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Files New U.S. Patent Application for Water-Soluble Cannabinoid Molecules
May 5, 2020
AXIM® Biotechnologies Files New U.S. Patent Application for Water-Soluble Cannabinoid Molecules
April 28, 2020
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Receives New U.S. Patent Issuance for Chewing Gum Comprising Cannabinoids and Nicotine
April 8, 2020
AXIM® Biotechnologies Receives New U.S. Patent Issuance for Chewing Gum Comprising Cannabinoids and Nicotine to Treat or Alleviate Tobacco Smoking
April 7, 2020
AXIM® Biotechnologies Completes Pre-Clinical Drug Studies on New Compound Proving Tenfold Greater Inhibition of Tumor Metastasis Than Parent Compound
March 24, 2020
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Completes Acquisition of Oncology Research and Development Company Sapphire Biotech, Inc.
March 24, 2020
AXIM® Biotechnologies Completes Acquisition of Oncology Research and Development Company Sapphire Biotech, Inc.
March 18, 2020
AXIM® Biotechnologies Nutraceutical Division Announces Launch of CBD-Based Gum for Professional and Amateur Golfers
February 26, 2020
Axim® Biotechnologies Completes First Phase of Pharmacokinetic Clinical Study on Cannabinoid-Based Gum With Dronabinol
February 18, 2020
AXIM® Biotechnologies Nutraceutical Division Announces Launch of Cannabinoid-Based Workout Gum and Other Upcoming Product Launches
February 12, 2020
AXIM® Biotechnologies Acquiree Sapphire Biotech, Inc. Signs Sponsored Research Agreement with Arizona State University to Develop Metastatic Cancer Inhibitor
February 10, 2020
AXIM® Biotechnologies Acquiree Sapphire Biotech, Inc. Signs License Agreement to Exclusively License Patent Rights in Cancer Technology
January 22, 2020
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies to Acquire Leading Oncology Research and Development Company Sapphire Biotech, Inc.
January 9, 2020
AXIM® Biotechnologies to Acquire Leading Oncology Research and Development Company Sapphire Biotech, Inc.
January 8, 2020
New Notice of U.S. Patent Allowance Granted to Axim® Biotechnologies for Suppository Formulations Comprising Cannabinoids
November 21, 2019
AXIM® Biotechnologies Nutraceutical Division Announces Cannabinoid-Based Wellness Gum Product Line at Benzinga Cannabis Capital Conference
October 22, 2019
AXIM® Biotechnologies Announces Cultivation Agreement to Establish Company’s First Domestic Industrial Hemp Source & Begins Harvesting
September 17, 2019
Medical Marijuana, Inc. Major Investment Company AXIM® Biotechnologies Begins GMP Manufacturing Of Cannabinoid-Based Gum With Dronabinol For Use In Upcoming Clinical Studies
September 12, 2019